C12N 2710/16661
Methods of inactivation or attenuation
C12N2710/16661 (Methods of inactivation or attenuation) appears on 112 US grants and 135 published applications in this corpus.
Search patents in C12N- Granted patents
- 112
- Published applications
- 135
- Assignees
- 91
- Inventors
- 246
- Latest grant
- 26 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1980 | 1 | 0 |
| 1981 | 1 | 0 |
| 1982 | 2 | 0 |
| 1983 | 2 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 1 | 0 |
| 1989 | 0 | 0 |
| 1990 | 1 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 1 | 0 |
| 1994 | 2 | 0 |
| 1995 | 0 | 0 |
| 1996 | 1 | 0 |
| 1997 | 0 | 0 |
| 1998 | 2 | 0 |
| 1999 | 1 | 0 |
| 2000 | 3 | 0 |
| 2001 | 6 | 0 |
| 2002 | 1 | 11 |
| 2003 | 6 | 8 |
| 2004 | 3 | 4 |
| 2005 | 4 | 4 |
| 2006 | 1 | 5 |
| 2007 | 2 | 1 |
| 2008 | 1 | 4 |
| 2009 | 2 | 6 |
| 2010 | 6 | 4 |
| 2011 | 1 | 9 |
| 2012 | 2 | 2 |
| 2013 | 2 | 5 |
| 2014 | 9 | 4 |
| 2015 | 2 | 5 |
| 2016 | 4 | 4 |
| 2017 | 4 | 10 |
| 2018 | 5 | 4 |
| 2019 | 9 | 5 |
| 2020 | 7 | 9 |
| 2021 | 2 | 3 |
| 2022 | 4 | 5 |
| 2023 | 2 | 9 |
| 2024 | 4 | 6 |
| 2025 | 4 | 5 |
| 2026 | 1 | 3 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Oncolytic virus compositions and methods for the treatment of cancer26 May 2026US 12,637,510 B2City of Hope
- Viral vectors for cancer therapy22 Jul 2025US 12,364,775 B2Krystal Biotech, Inc.
- High-transducing HSV vectors15 Apr 2025US 12,275,949 B2PeriphaGen, Inc.
- Replication-competent controlled alpha-herpesvirus vectors and uses therefore25 Mar 2025US 12,257,300 B2HSF Pharmaceuticals SA
- Engineered Herpes Simplex Virus-1 (HSV-1) vectors and uses thereof28 Jan 2025US 12,209,250 B2Massachusetts Institute of Technology
- Viral Vectors for Cancer Therapy30 Apr 2026US 2026/0115327 A1Krystal Biotech, Inc.
- Modified oncolytic herpes simplex virus (ohsv) and methods of use thereof9 Apr 2026US 2026/0097135 A1The General Hospital Corporation
- Transcriptional and translational dual regulated oncolytic herpes simplex virus vectors2 Apr 2026US 2026/0091069 A1Virogin Biotech Canada Ltd
- Method for treating glioma with ohsv22 Oct 2025US 2025/0302945 A1Binhui Biopharmaceutical Co., Ltd.
- Transcriptional and translational dual regulated oncolytic herpes simplex virus vectors22 May 2025US 2025/0161384 A1Virogin Biotech Canada Ltd
Most cited
By later US patents
- Antiviral method, agents and apparatus95US 4,915,683 AThe Medical College of Wisconsin, Inc. · 1990
- Method of eradicating infectious biological contaminants46US 5,304,113 AMCW Research Foundation, Inc. · 1994
- Method of inactivation of viral and bacterial blood contaminants with quinolines as photosensitizer42US 5,798,238 ABaxter International Inc. · 1998
- Herpes simplex virus-1 Glycoprotein C mutants for treating unwanted hyperproliferative cell growth41US 6,723,316 B2Onyx Pharmaceuticals, Inc. · 2004
- Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response41US 7,731,952 B2New York University · 2010